Key Insights

Highlights

Treatment Research

4 treatments under study, led by Dpa714 Petmri

Research Leaders

7 sponsors active, led by University of Alabama at Birmingham

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Early Phase 1 (1)
Phase 4 (1)

Trial Status

Recruiting3

Clinical Trials (3)

Showing 3 of 3 trials
NCT07781501RecruitingPrimary

Long-Term Study of COVID-19 Infection and Long COVID

NCT05656105Early Phase 1RecruitingPrimary

Positron Emission Tomography (PET) Imaging of Neuroinflammation in Patients With Neurological Dysfunction After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Infection

NCT06792214Phase 4RecruitingPrimary

Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial

Showing all 3 trials

Research Network

Common Treatments

  • Dpa714 Petmri1
  • Remdesivir1
  • This Study Is Observational Only Patients Who Have Previously Tested Positive For Sarscov2 Infection Or Are Experiencing Ongoing Symptoms1
  • Nirmatrelvirritonavir1

Active Sponsors

  • University of Alabama at Birmingham1
  • Niagara Health System1
  • University of North Carolina, Chapel Hill1
  • Mount Sinai Hospital, Canada1
  • Unity Health Toronto1

Top Investigators

Activity Timeline